Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America, and Europe. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 705,000 |
| EBITDA | $-874.67M |
| Operating Margin | 0.00% |
| Return on Equity | -192.50% |
| Return on Assets | -101.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.70 |
| Price-to-Book | 17.30 |
| Price-to-Sales (TTM) | 3891.31 |
| EV/Revenue | 6425.28 |
| EV/EBITDA | -5.32 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $797.75M |
| Float | $152.29M |
| % Insiders | 80.89% |
| % Institutions | 15.41% |
Volatility is currently expanding
NEW YORK, July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Summit posts a wider Q2 loss with no revenues as ivonescimab advances through late-stage studies, undergoes FDA review & gains new development collaborations.
Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the second quarter and six months ended June 30, 2026 and provided an update on clinical and operational progress. “The clinical momentum of ivonescimab continues to build, with two recent key data readouts that significantly bolster our development progress. At ASCO, the landmark HARMONi-6 results established the first head-to-head Phase III study in any tumor type to demonstrate a meaningf.
Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab in kidney cancer, expanding its late-stage development.
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne.
Summit Therapeutics is upgraded from 'Hold' to 'Buy' following FDA acceptance of its BLA for ivonescimab + chemotherapy in EGFR-mutant NSCLC. SMMT's OS data in the HARMONi phase 3 trial improved over time, with hazard ratios dropping from 0.79 to 0.76 in both Western and ITT populations. Akeso's HARMONi-6 trial showed ivonescimab + chemo achieved a 34% reduction in risk of death versus tislelizumab + chemo in 1st-line NSCLC.
President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced results of an updated overall survival (OS) analysis from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab. Ivonescimab plus platinum-doublet chemotherapy in this trial continues to show a positive OS trend and a consistent efficacy and safety profile in Asian and western patients when compared to chemotherapy alone. The HARMONi.
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SMMT and any ticker you trade — then tracks every position and per-strategy win rate.
